argenx to Present New VYVGART and Empasiprubart Data at 2025 AANEM and MGFA Meetings

argenx SE announced it will present a broad set of data at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session, taking place October 29 through November 1 in San Francisco. The presentations will highlight updates from the company’s VYVGART® (efgartigimod) programs and the investigational agent empasiprubart, across a range of rare autoimmune and neuromuscular conditions.

Among the data being shared are results from the pivotal Phase 3 ADAPT SERON study evaluating VYVGART in adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody negative. According to the company, the study demonstrated clinically meaningful improvements in disease activity across all three subtypes of this seronegative population: triple negative, MuSK-positive, and LRP4-Ab seropositive patients.

Additionally, interim findings from the ADAPT Jr study will be presented. This pediatric-focused trial assesses age-appropriate dosing, safety, and clinical effect of VYVGART in children living with generalized myasthenia gravis.

Data on chronic inflammatory demyelinating polyneuropathy (CIDP) will include updates on VYVGART Hytrulo, highlighting functional improvements, long-term safety, and real-world patient characteristics. These findings are presented alongside the designs of two ongoing Phase 3 trials for empasiprubart in CIDP, named EMVIGORATE and EMNERGIZE.

In the area of multifocal motor neuropathy (MMN), argenx will share clinical efficacy and safety results from the Phase 2 ARDA study of empasiprubart, and provide an overview of the planned Phase 3 EMPASSION trial comparing empasiprubart to IVIg. The company will also present real-world data on disease burden, treatment patterns, and quality of life in MMN, aiming to inform ongoing development of therapeutic approaches that may reduce reliance on existing treatment modalities.

In total, more than 40 abstracts will be presented across generalized myasthenia gravis, CIDP, MMN, and idiopathic inflammatory myopathies (IIM), reflecting the company's focus on rare neuromuscular diseases. In a statement, Chief Medical Officer Luc Truyen, M.D., Ph.D., noted the presentations reflect the progress of argenx’s clinical development programs, including the expansion of VYVGART into new patient populations and the advancement of empasiprubart.